The NF-kappaB pathway and the successful application of anti-inflammatory and angiostatic therapy in Langerhans' cell histiocytosis.
R E
RE
Brown
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism*; D015398:Signal Transduction
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D016328:NF-kappa B